Video

Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Author(s):

Loretta J. Nastoupil, MDMarc S. Hoffman, MD

Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Sumanta Kumar Pal, MD, FASCO,
Sattva S. Neelapu, MD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Benjamin J. Solomon, MBBS, PhD
May 31st 2024

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

FDA
May 30th 2024

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy

Pancreatic Cancer
May 29th 2024

CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer